AbbVie and J&J claim new Imbruvica okay in USAbbVie and Johnson & Johnson’s Imbruvica has become the first chemo-free treatment for first-line chronic lymphocytic leukaemia (CLL) Share XAbbVie and J&J claim new Imbruvica okay in UShttps://pharmaphorum.com/news/abbvie-and-jj-claim-new-imbruvica-okay-in-us/
AbbVie wobbles as biosimilars bite HumiraAbbVie’s shares slipped ahead of the weekend when its fourth-quarter revenues missed forecasts, after biosimilar competition – particularly Share XAbbVie wobbles as biosimilars bite Humirahttps://pharmaphorum.com/news/abbvie-wobbles-as-biosimilars-bite-humira/
AbbVie and J&J’s Imbruvica fails pancreatic cancer testAbbVie and Johnson & Johnson’s hopes of adding pancreatic cancer to the repertoire of oncology blockbuster Imbruvica has Share XAbbVie and J&J’s Imbruvica fails pancreatic cancer testhttps://pharmaphorum.com/news/abbvie-and-jjs-imbruvica-fails-pancreatic-cancer-test/
R&D roundup – Sage impresses at JP MorganOne of the biggest headline-grabbers at the 2019 JP Morgan Healthcare conference this week was Sage Therapeutics unveiling Share XR&D roundup – Sage impresses at JP Morganhttps://pharmaphorum.com/r-d/views-analysis-r-d/rd-roundup-sage-impresses-at-jp-morgan/
AbbVie suffers fresh setback with lung cancer drug Rova-TAbbVie has suffered a further setback with its oncology drug Rova-T, after early data from a lung cancer Share XAbbVie suffers fresh setback with lung cancer drug Rova-Thttps://pharmaphorum.com/news/abbvie-suffers-fresh-setback-with-lung-cancer-drug-rova-t/
AbbVie, Pfizer reach licencing agreement for biosimilar HumiraAbbVie has granted a non-exclusive patent license allowing Pfizer to sell its Humira (adalimumab) biosimilar in many countries Share XAbbVie, Pfizer reach licencing agreement for biosimilar Humirahttps://pharmaphorum.com/news/abbvie-pfizer-reach-licencing-agreement-for-biosimilar-humira/
NHS saving £300m with Humira biosimilar dealThe NHS is to save £300 million after striking deals with several manufacturers of low cost biosimilars of Share XNHS saving £300m with Humira biosimilar dealhttps://pharmaphorum.com/news/nhs-saving-300m-with-humira-biosimilar-deal/
BMS, AbbVie get FDA OK for new myeloma regimenBristol-Myers Squibb and AbbVie have picked up another FDA approval for their multiple myeloma drug Empliciti that they Share XBMS, AbbVie get FDA OK for new myeloma regimenhttps://pharmaphorum.com/news/bms-abbvie-get-fda-ok-for-new-myeloma-regimen/
AbbVie, Roche eye first-line use of Venclexta in leukaemiaAbbVie and Roche’s Venclexta has hit the mark in a combination trial that could help it move into Share XAbbVie, Roche eye first-line use of Venclexta in leukaemiahttps://pharmaphorum.com/news/abbvie-roche-venclexta-leukaemia/
